ATC Group: G04BE Drugs used in erectile dysfunction

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of G04BE in the ATC hierarchy

Level Code Title
1 G Genito urinary system and sex hormones
2 G04 Urologicals
3 G04B Other urologicals, incl. antispasmodics
4 G04BE Drugs used in erectile dysfunction

Group G04BE contents

Code Title
G04BE01 Alprostadil
G04BE02 Papaverine
G04BE03 Sildenafil
G04BE04 Yohimbin
G04BE06 Moxisylyte
G04BE07 Apomorphine
G04BE08 Tadalafil
G04BE09 Vardenafil
G04BE10
G04BE11
G04BE30 Combinations
G04BE52 Papaverine, combinations

Active ingredients in G04BE

Active Ingredient Description
Alprostadil

Alprostadil is chemically identical to prostaglandin E1, the actions of which include vasodilatation of blood vessels in the erectile tissues of the corpora cavernosa and increase in cavernosal artery blood flow, causing penile rigidity.

Apomorphine

Apomorphine is a direct stimulant of dopamine receptors and while possessing both D1 and D2 receptor agonist properties does not share transport or metabolic pathways with levodopa. Its actions on parkinsonian motor disability are likely to be mediated at post-synaptic receptor sites.

Avanafil

Avanafil is a highly selective and potent, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5. When sexual stimulation causes the local release of nitric oxide, inhibition of PDE5 by avanafil produces increased levels of cGMP in the corpus cavernosum of the penis. This results in smooth muscle relaxation and inflow of blood into the penile tissues, thereby producing an erection.

Papaverine
Sildenafil

Sildenafil is a potent and selective inhibitor of cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type 5 (PDE5), the enzyme that is responsible for degradation of cGMP. Apart from the presence of this enzyme in the corpus cavernosum of the penis, PDE5 is also present in the pulmonary vasculature. Sildenafil, therefore, increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation.

Tadalafil

Tadalafil is a selective, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). When sexual stimulation causes the local release of nitric oxide, inhibition of PDE5 by tadalafil produces increased levels of cGMP in the corpus cavernosum. This results in smooth muscle relaxation and inflow of blood into the penile tissues, thereby producing an erection. The effect of PDE5 inhibition on cGMP concentration in the corpus cavernosum is also observed in the smooth muscle of the prostate, the bladder and their vascular supply. The resulting vascular relaxation increases blood perfusion which may be the mechanism by which symptoms of benign prostatic hyperplasia are reduced.

Udenafil

Udenafil, an oral therapy for the treatment of erectile dysfunction (ED), is a pyrazolopyrimidinone class and a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) of the corpus cavernosum, which induce potent penile erection.

Vardenafil

Vardenafil is a potent and selective inhibitor of the cGMP specific phosphodiesterase type 5 (PDE5), the most prominent PDE in the human corpus cavernosum. Vardenafil is an oral therapy for the improvement of erectile function in men with erectile dysfunction. In the natural setting, i.e. with sexual stimulation it restores impaired erectile function by increasing blood flow to the penis.

Yohimbine

Related product monographs

Title Information Source Document Type  
CAVERJECT Powder for solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
CIALIS 2.5 mg Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
CIALIS 5 mg Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
EDEX Powder for solution FDA, National Drug Code (US) MPI, US: SPL/Old
GRANPIDAM Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
LEVITRA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
MUSE Urethral Stick Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
MYSILDECARD Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
PROSTIN E2 Concentrate for solution for infusion Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
PROSTIN E2 Vaginal tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
QUATOR Film-coated tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC
REVATIO Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
REVATIO Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
SPEDRA Tablet European Medicines Agency (EU) MPI, EU: SmPC
STAXYN Tablet, orally disintegrating FDA, National Drug Code (US) MPI, US: SPL/PLR
STENDRA Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
TADALAFIL MYLAN Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
TALMANCO Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
TRIPAN 20mg Film-coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
TRIPAN 5mg Film-coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
VIAGRA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
VIAGRA Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
VIVANZA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
ZYDENA Tablet Web Search MPI, Generic